So far, therapies have targeted insulin-sensitive organs such as muscles, liver and adipose tissue to improve hyperglycemia, hyperinsulinemia and resistance to insulin (Altaf et al., 2014). This evidence concerns the gene INS and Hyperinsulinemia.